Cell and gene therapy sector remains strong despite challenges: ARM CEO
The cell and gene therapy sector is “quite strong” despite the regulatory, investment, and manufacturing challenges facing the industry, according to Janet Lambert, CEO of the Alliance for Regenerative Medicine (ARM). Lambert spoke with ScienceBoard.net about developments in the industry. Read More
Machine Bio seeks to fundamentally change how biotechs make protein
Protein purification is one of the biggest bottlenecks for biotechnology companies. However, startup Machine Bio is developing a next-generation protein synthesis platform that can produce pure protein from DNA in hours, minutes, or continuously using a single step process. Founders David Marash and Jack Fernandes spoke with ScienceBoard.net at the 2022 Biotechnology Innovation Organization International Convention. Read More
How one CDMO is navigating the global supply chain disruption
The COVID-19 pandemic has disrupted supply chains and production schedules around the world, forcing contract development and manufacturing organizations (CDMOs) to adapt. In a video interview at the 2022 Biotechnology Innovation Organization International Convention, Federico Pollano of Rentschler Biopharma discussed how the company is navigating the worldwide supply chain disruption. Read More
A case study on partnering between patient advocacy organizations and biotech
Last week's 2022 Biotechnology Innovation Organization (BIO) International Convention in San Diego gave patient advocacy organizations and biotech companies the first opportunity in three years to meet in person with the potential for partnering. However, it was a meeting at BIO 2019 between CMT Research Foundation and DTx Pharma that could serve as a model for such partnerships. Read More
NIH seeks industry partners for technology transfer
The National Institutes of Health (NIH) is the world’s largest public funder of biomedical research. ScienceBoard.net spoke with Michael Salgaller of the National Cancer Institute at the 2022 Biotechnology Innovation Organization International Convention about NIH’s technology transfer professionals who work with its scientist inventors to find commercial partners to take their inventions to market. Read More
Estonia’s ambitious plans to grow its biotech industry
The Baltic state of Estonia's biotech industry is expected to grow tenfold this decade and offers significant opportunities for Estonian companies. ScienceBoard.net spoke with Andres Sutt, Estonia’s minister of entrepreneurship and information technology, at the 2022 Biotechnology Innovation Organization International Convention in San Diego about the country’s ambitious plans to grow its biotech industry. Read More
Fauna Bio leverages animal genomics, hibernation biology to target human diseases
Biotech company Fauna Bio is leveraging animal genomics and hibernation biology to develop novel translational therapeutics for disease prevention and reduce the impact of age-related diseases in humans. ScienceBoard.net spoke with co-founder and CEO Ashley Zehnder about the intersection of animal genomics, hibernation biology, and human diseases. Read More
Using the power of plants to develop novel biopharmaceuticals
Biologics manufacturing company iBio is using plants as bioreactors to develop and manufacture therapeutics and vaccines. ScienceBoard.net spoke with CEO Tom Isett at the 2022 Biotechnology Innovation Organization International Convention about the company’s technology, programs, and more. Read More
Apeiron Biologics' spinout invIOs targets solid tumors with novel cell therapy platform
Apeiron Biologics' spinout invIOs has a proprietary cell therapy platform for the modulation of intracellular immuno-oncology targets that enables rapid treatment of cancer patients using their own immune cells with short out-of-body time in out-patient settings. ScienceBoard.net spoke with invIOs’ CEO Peter Llewellyn-Davies at the 2022 Biotechnology Innovation Organization International Convention in San Diego. Read More
Overcoming the challenges of off-the-shelf allogeneic cell therapies
Chimeric antigen receptor T-cell therapy has emerged as one of the major breakthroughs in cancer immunotherapy in the last decade. In a video interview at the 2022 Biotechnology Innovation Organization International Convention in San Diego, Dr. Jason Litten discussed the challenges that need to be overcome for allogeneic T cells to reach clinical success. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter